Plandai Biotechnology's CEO Discusses Direction of Medical Marijuana Subsidiary

NEW YORK, NY--(Marketwired - Dec 12, 2013) -  Plandaí Biotechnology's (OTCQB: PLPL) subsidiary, Cannabis Biosciences, Inc., will be developing and testing a botanical extract derived from cannabis, and the company's CEO, Roger Duffield, announced it will address neural disorders with its marijuana research. In that announcement Duffield said, "We believe that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, and post-concussion syndrome."

Plandaí, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, expects to use its licensed Phytofare™ and Pheroid™ technologies to produce an FDA approved Phytofare™ cannabinoid complex that can address neural disorders without introducing the psychoactive element of THC to its treatments.

Duffield said, "Our research affirms that damage to the CB1 and CB2 brain receptors contributes to several neuron diseases. Cannabis is rich in neuron-beneficial phytocannabinoids including Δ9-THC; however, Δ9-THC taken in an oral preparation converts in the liver to 11-hydroxy metabolite. This new chemical demonstrates high levels of psycho-activity and is significantly less effective in scavenging free radicals. Essentially, you get the psychotropic aspects of the drug with none of the medicinal benefits."

Unlike other biotechs engaged in marijuana research, Plandaí's extraction and hydrodynamic sheering process combined with its Pheroid™ technology, should allow it to produce an extract that captures and enhances the phytocannabinoids while ideally leaving behind the phychotropic effects. 

According to the company, Δ9-THC has similar antioxidant activities as the catechins in green tea by having affinity to the CB1 and CB2 neuron receptors. Plandaí's CEO says, "The science suggests we can produce a highly bioavailable complex that has little if any psychotropic effects and that can deliver a clinical dose to cellular tissues."

Plandaí stated its immediate goal is to undertake the profiling of the Phytofare™ Cannabinoid Complex with in-vitro testing starting within six months. Plandaí anticipates beginning animal trials within twelve months and expects to eventually gain FDA approval for human clinical trials specifically aimed at a number of neural disorders.

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, Interviews and Feature Articles.